Jana Jurečeková1, Henrieta Drobková2,3, Miroslava Šarlinová1, Eva Babušíková4, Monika Kmeťová Sivoňová4, Tatiana Matáková1,4, Ján Kliment5, Erika Halašová1,3. 1. Department of Molecular Medicine, Jessenius Faculty of Medicine in Martin, Biomedical Center Martin, Comenius University in Bratislava, Martin, Slovakia. 2. Department of Urology, Jessenius Faculty of Medicine and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia henrieta.drobkova@gmail.com. 3. Department of Medical Biology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. 4. Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. 5. Department of Urology, Jessenius Faculty of Medicine and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia.
Abstract
BACKGROUND/AIM: Interleukin-6 is an important modulator of inflammation, which is one of the factors involved in prostate cancer. The aim of the study was to evaluate the possible association of the IL-6 -174 polymorphism (rs1800795) with the risk of prostate cancer development and progression. MATERIALS AND METHODS: The study population consisted of 446 prostate cancer patients, 377 benign prostatic hyperplasia (BHP) patients and 276 healthy men. Genotyping was performed by PCR-RFLP analysis. IL-6 plasma levels were measured by the ELISA method. RESULTS: The GC genotype (OR=0.61, p=0.005) and C allele (OR=0.8, p=0.04) of the IL-6 -174 polymorphism were significantly associated with prostate cancer. No genotype was associated with BHP. IL-6 plasma levels were significantly increased in prostate cancer patients compared to both healthy men (p=0.02) and BHP patients (p=0.008). No significant differences were observed in IL-6 plasma levels in connection with IL-6 -174 genotypes. CONCLUSION: The IL-6 -174 polymorphism was significantly associated with prostate cancer in Slovak patients. Copyright
BACKGROUND/AIM: Interleukin-6 is an important modulator of inflammation, which is one of the factors involved in prostate cancer. The aim of the study was to evaluate the possible association of the IL-6 -174 polymorphism (rs1800795) with the risk of prostate cancer development and progression. MATERIALS AND METHODS: The study population consisted of 446 prostate cancerpatients, 377 benign prostatic hyperplasia (BHP) patients and 276 healthy men. Genotyping was performed by PCR-RFLP analysis. IL-6 plasma levels were measured by the ELISA method. RESULTS: The GC genotype (OR=0.61, p=0.005) and C allele (OR=0.8, p=0.04) of the IL-6 -174 polymorphism were significantly associated with prostate cancer. No genotype was associated with BHP. IL-6 plasma levels were significantly increased in prostate cancerpatients compared to both healthy men (p=0.02) and BHP patients (p=0.008). No significant differences were observed in IL-6 plasma levels in connection with IL-6 -174 genotypes. CONCLUSION: The IL-6 -174 polymorphism was significantly associated with prostate cancer in Slovak patients. Copyright
Authors: M P Santos; J N Pereira; R W Delabio; M A C Smith; S L M Payão; L C Carneiro; M S Barbosa; L T Rasmussen Journal: Braz J Med Biol Res Date: 2021-05-17 Impact factor: 2.590